At this time, I'd like to welcome everyone to Xenon Pharmaceuticals ... and potential results from clinical trials, the potential efficacy, safety profile, future development plans in current ...

"Xenon's leadership in the Kv7 landscape is unmatched as our lead molecule, azetukalner, represents the only highly potent, selective Kv7 potassium channel opener in development for multiple ...

“Xenon’s leadership in the Kv7 landscape is unmatched as our lead molecule, azetukalner, represents the only highly potent, selective Kv7 potassium channel opener in development for multiple ...

"Xenon's leadership in the Kv7 landscape is unmatched ... development for multiple indications that is backed by long-term efficacy and safety data with over 600-patient years of exposure in ...

“Xenon’s leadership in the Kv7 landscape is unmatched as our lead molecule, azetukalner, represents the only highly potent, selective Kv7 potassium channel opener in development for ...

VANCOUVER, British Columbia and BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc ... indications that is backed by long-term efficacy and safety data with over 600-patient ...

“Xenon’s leadership in the Kv7 landscape is ... in development for multiple indications that is backed by long-term efficacy and safety data with over 600-patient years of exposure in patients ...